sur SENSORION (EPA:ALSEN)
Leadership Transition at Sensorion amid Strategic Focus on Hearing Loss Therapies
Sensorion, a biotechnology company focused on hearing loss therapies, announced leadership changes effective immediately. CEO Nawal Ouzren steps down for personal reasons, with Chairman Amit Munshi assuming the role of Interim CEO. Ouzren will consult temporarily for a smooth transition, while the board searches for a permanent CEO.
Ouzren highlighted the company's strategic position, underpinned by recent €60 million financing led by Sanofi for advancing key pipeline assets like SENS-601, targeting GJB2 gene mutations linked to congenital deafness. Upcoming milestones include SENS-601 clinical trial applications and data from SENS-501 trials.
The transition occurs as Sensorion strengthens its focus on gene therapy and small molecule programs, aiming to address significant unmet needs in hearing loss disorders. The management vows to maintain developmental timelines and growth objectives.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SENSORION